A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

NCT06501196 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Preleukemia
Myelodysplastic Syndromes
Refractory Acute Myeloid Leukemia

Interventions

DRUG: BH-30236
DRUG: Venetoclax

Sponsor

BlossomHill Therapeutics